W Stohl
Overview
Explore the profile of W Stohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, et al.
Lupus
. 2018 May;
27(9):1489-1498.
PMID: 29807477
Objective To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. Methods This was a 24-week, open-label extension following...
2.
Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, Vollenhoven R, et al.
Arthritis Rheumatol
. 2018 Apr;
70(8):1256-1264.
PMID: 29671280
Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were...
3.
Merrill J, van Vollenhoven R, Buyon J, Furie R, Stohl W, Morgan-Cox M, et al.
Ann Rheum Dis
. 2015 Aug;
75(2):332-40.
PMID: 26293163
Objectives: To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods: This randomised, placebo-controlled study enrolled 1124...
4.
Tak P, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven R, Stohl W, et al.
Ann Rheum Dis
. 2010 Oct;
70(1):39-46.
PMID: 20937671
Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of...
5.
Collins C, La D, Yang H, Massin F, Gibot S, Faure G, et al.
Ann Rheum Dis
. 2008 Dec;
68(11):1768-74.
PMID: 19054829
Objective: To determine whether synovial expression of triggering receptor expressed on myeloid cells 1 (TREM-1) is upregulated in patients with distinct types of inflammatory or non-inflammatory arthritis. Methods: Synovial fluid...
6.
La D, Collins C, Yang H, Migone T, Stohl W
Ann Rheum Dis
. 2007 Oct;
67(8):1132-8.
PMID: 17967830
Objective: To assess the effects of tumour necrosis factor (TNF) antagonist therapy on B lymphocyte stimulator (BLyS) expression in patients with rheumatoid arthritis (RA). Methods: Blood from 38 patients with...
7.
Cambridge G, Isenberg D, Edwards J, Leandro M, Migone T, Teodorescu M, et al.
Ann Rheum Dis
. 2007 Oct;
67(7):1011-6.
PMID: 17962238
Objective: To assess the relationships between serum B lymphocyte stimulator (BLyS) levels, autoantibody profile and clinical response in patients with systemic lupus erythematosus (SLE) following rituximab-based B cell depletion therapy...
8.
Schaller M, Stohl W, Tan S, Benoit V, Hilbert D, Ditzel H
Ann Rheum Dis
. 2004 Oct;
64(5):743-9.
PMID: 15458959
Background: In K/BxN mice, anti-glucose-6-phosphate isomerase (GPI) antibodies (Abs) are arthritogenic, and their transfer into naive mice induces arthritis. Anti-GPI Abs develop in many human patients with RA and are...
9.
Stohl W, Metyas S, Tan S, Cheema G, Oamar B, Roschke V, et al.
Ann Rheum Dis
. 2004 Aug;
63(9):1096-103.
PMID: 15308519
Objective: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and...
10.
Stohl W
Lupus
. 2004 Jul;
13(5):317-22.
PMID: 15230285
B lymphocyte stimulator (BLyS) is a vital B cell survival factor. Overexpression of BLyS in mice may lead to systemic lupus erythematosus (SLE)-like disease, and treatment of bona fide SLE...